The Week in Review #41 We Are Still Witnessing … The bizarre market performance that started …

Regeneron Product REGN-EB3 Saving Lives Regeneron (REGN) announced that an independent monitoring board ended its investigational product …

Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and …

Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed …

Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial …

Rhythm Pharmaceuticals From Rhythm Pharmaceuticals (RYTM) we learned that positive, top-line results from two pivotal Phase 3 …

In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. …

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. …

Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. …

Halozyme and argenx Collaboration argenx (ARGX) dosed the first subject in phase 1 clinical trial for the …